Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
Laboratory data before and after long-term VPA monotherapy treatment (%)Laboratory itemsBaseline (%)During treatment (%)P-valueALT > 40 IU/L3 (2.2)4 (1.9)1.000AST > 40 IU/L14 (10.3)27 (12.9)0.471Serum ammonia > 72 μmol/L5 (5.2)10 (11.9)0.105Serum sodium < 135 mmol/L3 (3.0)6 (6.3)0.324Serum calcium < 2.2 mmol/L8 (7.2)12 (11.7)0.26525-(OH)-VitD < 30 ng/ml21 (87.5)15 (55.6)0.012*PLT < 150 × 109/L4 (2.5)11 (4.4)0.305VPA Valproic acid, ALT Alanine aminotransferase, AST Aspartate aminotransferase, 25-(OH)-VitD 25 hydroxy-vitamin D, PLT Platelet*(P < 0.05)Laboratory data in different first-visit age groups after over two years of VPA monotherapy treatment (%)Laboratory itemsAge at first visitP-value < 1 year1: 3 years ≥ 3 yearsALT > 40 IU/L0 (0.0)0 (0.0)4 (3.3)0.485AST > 40 IU/L15 (34.9)a、b4 (8.9)a8 (6.6)b < 0.001Serum ammonia > 72 μmol/L6 (30.0)c2 (9.1)2 (4.8)c0.015Serum sodium < 135 mmol/L3 (13.0)1 (4.2)2 (4.0)0.357Serum calcium < 2.2 mmol/L1(4.3)0 (0.0)d11 (20.0)d0.01525-(OH)-VitD < 30 ng/ml3 (37.5)3 (42.9)9 (75.0)0.227PLT < 150 × 109/L1 (2.0)2 (3.4)6 (4.2)0.900① The three age groups were compared in pairs and was considered to have statistical significance when P < 0.017.② Pa = 0.003, Pb < 0.001, Pc = 0.011, Pd = 0.014, statistical significance was foundVPA Valproic acid, ALT Alanine aminotransferase, AST Aspartate aminotransferase, 25-(OH)-VitD 25 hydroxy-vitamin D, PLT Platelet
Source: ADRs incidence from laboratory data. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Study design awaiting verification.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.
Meta-analysis unclear · Blinding unclear / not reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
Information of sex, age at the first visit, time of follow up, diagnostic data (including primary and other diagnoses), the time of first dose of VPA, the duration of VPA treatment, the medical record (including the record of out-patient and emergency treatment, admission and discharge, and the courses), and auxiliary examination results of all eligible patients was collected from the epilepsy clinical data platform of the Shenzhen Children’s Hospital.
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
The safety of valproic acid treatment in children with epilepsy: a retrospective real-world research
Study design awaiting verification · Acta Epileptologica · 2024
Original publication title
The safety of valproic acid treatment in children with epilepsy: a retrospective real-world research
© The Author(s) 2024
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What background does the paper provide?
Liver damage, coagulopathy, hyperammonemia, fracture, menstrual disorder and amenorrhea are the most concerned adverse drug reactions of valproic acid (VPA). This study was aimed to retrospectively investigate the incidence of adverse drug reactions of VPA in the real world and its association with the age of patients and duration of treatment in order to obtain the safety data of VPA in children with epilepsy.
Source: BackgroundAbstract: What methods does the paper describe?
A total of 1943 patients diagnosed as epilepsy by the Pediatric Neurology Department of Shenzhen Children’s Hospital between December 2013 and December 2023, were included in the study. They received VPA as an initial treatment, and had followed up examinations over a time span of at least two years focusing on the adverse drug reactions of VPA.
Source: MethodsAbstract: Results
There was no significant difference in the incidence of liver damage, coagulation test abnormalities, and nasal bleeding during VPA monotherapy (30 to 90 days, 90 to 180 days, and > 2 years). Adolescent female patients (first visit age ≥ 12 years) showed no significant difference in the incidence of adverse reactions and abnormal ultrasound of the reproductive system pre: versus post-treatment at the first visit, similar for those below 12 years. However, laboratory blood tests revealed significantly age-dependent changes in certain biochemical markers. Two patients stopped VPA treatment due to thrombocytopenia and ovarian cystic mass comorbid with endometrial hyperplasia, recovering after VPA withdrawal.
Source: ResultsAbstract: Conclusions
The initial monotherapy of VPA is generally safe in children with epilepsy of all age ranges. In the real world, VPA does not increase the risk of liver damage, coagulation disorder, elevated blood ammonia, fractures, or low serum sodium, but may significantly decrease the platelet count at 3, 6, 12, and 24 months of treatment. There is no evidence showing that VPA may increase the incidence of impairment of adolescent female reproductive system. Among children under 1 year old, it is recommended to monitor the levels of serum ammonia and aspartate aminotransferase carefully.
Source: ConclusionsAuthors’ abstract
Background
Liver damage, coagulopathy, hyperammonemia, fracture, menstrual disorder and amenorrhea are the most concerned adverse drug reactions of valproic acid (VPA). This study was aimed to retrospectively investigate the incidence of adverse drug reactions of VPA in the real world and its association with the age of patients and duration of treatment in order to obtain the safety data of VPA in children with epilepsy.
Methods
A total of 1943 patients diagnosed as epilepsy by the Pediatric Neurology Department of Shenzhen Children’s Hospital between December 2013 and December 2023, were included in the study. They received VPA as an initial treatment, and had followed up examinations over a time span of at least two years focusing on the adverse drug reactions of VPA.
Results
There was no significant difference in the incidence of liver damage, coagulation test abnormalities, and nasal bleeding during VPA monotherapy (30 to 90 days, 90 to 180 days, and > 2 years). Adolescent female patients (first visit age ≥ 12 years) showed no significant difference in the incidence of adverse reactions and abnormal ultrasound of the reproductive system pre: versus post-treatment at the first visit, similar for those below 12 years. However, laboratory blood tests revealed significantly age-dependent changes in certain biochemical markers. Two patients stopped VPA treatment due to thrombocytopenia and ovarian cystic mass comorbid with endometrial hyperplasia, recovering after VPA withdrawal.
Conclusions
The initial monotherapy of VPA is generally safe in children with epilepsy of all age ranges. In the real world, VPA does not increase the risk of liver damage, coagulation disorder, elevated blood ammonia, fractures, or low serum sodium, but may significantly decrease the platelet count at 3, 6, 12, and 24 months of treatment. There is no evidence showing that VPA may increase the incidence of impairment of adolescent female reproductive system. Among children under 1 year old, it is recommended to monitor the levels of serum ammonia and aspartate aminotransferase carefully.
Trial registration
ChiCTR2300075115.
Publication and source details
Original title: The safety of valproic acid treatment in children with epilepsy: a retrospective real-world research
Xiner Chen; Yujie Zhang; Xinan Liu; Ruoyu Tan; Dezhi Cao; Li Chen; Yan Hu; Bing Li; Tieshuan Huang; Qiang Zhou; Jialun Wen; Jianxiang Liao
Acta Epileptologica · 2024
© The Author(s) 20242024https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T08:05:46.977830+00:00
DOI: 10.1186/s42494-024-00188-x · PMC11960323